Lars Grøvle

Lars Grøvle

Auto-generated profile, based on publicly available information

Lars Grøvle

Department of Rheumatology, Østfold Hospital Trust, Fredrikstad, Norway

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2012 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
AHAnne Julsrud Haugen
Anne Julsrud Haugen
JBJens Ivar Brox
Jens Ivar Brox
LGLars Grøvle
Lars Grøvle
AKAnne Keller
Anne Keller
BNBård Natvig
Bård Natvig
MGMargreth Grotle
Margreth Grotle
Few studies have investigated prognostic factors for patients with sciatica, especially for patients treated without surgery. The aim of this study was to identify factors associated with non-success after 1 and 2 years of follow-up and to test the prognostic value of surgical treatment for sciatica.

1 May 2014 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
LGLars Grøvle
Lars Grøvle
AHAnne J. Haugen
Anne J. Haugen
EHEivind Hasvik
Eivind Hasvik
BNBård Natvig
Bård Natvig
JBJens I. Brox
Jens I. Brox
MGMargreth Grotle
Margreth Grotle

18 May 2014 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
EHEivind Hasvik
Eivind Hasvik
ESElina Iordanova Schistad
Elina Iordanova Schistad
LGLars Grøvle
Lars Grøvle
AHAnne Julsrud Haugen
Anne Julsrud Haugen
CRCecilie Røe
Cecilie Røe
JGJohannes Gjerstad
Johannes Gjerstad
Earlier observations show that development of persistent pain may be associated with the genetic variability in the gene encoding for the μ-opioid receptor 1, the OPRM1 A118G (rs1799971). The aim of this study was to investigate the association between OPRM1 genotype and subjective health complaints in patients with radicular pain and disc herniation.

1 February 2012 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
LGLars Grøvle
Lars Grøvle
AHAnne J. Haugen
Anne J. Haugen
AKAnne Keller
Anne Keller
BNBård Natvig
Bård Natvig
JBJens I. Brox
Jens I. Brox
MGMargreth Grotle
Margreth Grotle

15 December 2017 in Trials
Verified
Journal Article
Open access
PDF file
KSKjersti Storheim
Kjersti Storheim
AEAnsgar Espeland
Ansgar Espeland
LGLars Grøvle
Lars Grøvle
JSJan Sture Skouen
Jan Sture Skouen
JAJörg Aßmus
Jörg Aßmus
JZJohn-Anker Zwart
John-Anker Zwart
A previous randomised controlled trial (RCT) of patients with chronic low back pain (LBP) and vertebral bone marrow (Modic) changes (MCs) on magnetic resonance imaging (MRI), reported that a 3-month, high-dose course of antibiotics had a better effect than placebo at 12 months’ follow-up. The present study examines the effects of antibiotic treatment in chronic LBP patients with MCs at the level of a lumbar disc herniation, similar to the previous study. It also aims to assess the cost-effectiveness of the treatment, refine the MRI assessment of MCs, and further evaluate the impact of the treatment and the pathogenesis of MCs by studying genetic variability and the gene and protein expression of inflammatory biomarkers. A double-blinded RCT is conducted at six hospitals in Norway, comparing orally administered amoxicillin 750 mg, or placebo three times a day, over a period of 100 days in patients with chronic LBP and type I or II MCs at the level of a MRI-confirmed lumbar disc herniation within the preceding 2 years. The inclusion will be stopped when at least 80 patients are included in each of the two MC type groups. In each MC type group, the study is designed to detect (β = 0.1, α = 0.05) a mean difference of 4 (standard deviation 5) in the Roland Morris Disability Questionnaire score between the two treatment groups (amoxicillin or placebo) at 1-year follow-up. The study includes cost-effectiveness measures. Blood samples are assessed for security measures and for possible inflammatory mediators and biomarkers at different time points. MCs are evaluated on MRI at baseline and after 12 months. A blinded intention-to-treat analysis of treatment effects will be performed in the total sample and in each MC type group. To ensure the appropriate use of antibiotic treatment, its effect in chronic LBP patients with MCs should be re-assessed. This study will investigate the effects and cost-effectiveness of amoxicillin in patients with chronic LBP and MCs at the level of a disc herniation. The study may also help to refine imaging and characterise the biomarkers of MCs. ClinicalTrials.gov, ID: NCT02323412 . Registered on 21 November 2014.

17 June 2013 in European Spine Journal
Verified
Journal Article
Closed access
PDF file
LGL. Grøvle
L. Grøvle
AHA. J. Haugen
A. J. Haugen
BNB. Natvig
B. Natvig
JBJ. I. Brox
J. I. Brox
MGM. Grotle
M. Grotle